Advanced glycation end products and vascular inflammation: Implications for accelerated atherosclerosis in diabetes

Cardiovascular Research

Volumn 63, Issue 4, 2004, Pages 582-592

  Basta, Giuseppina ^a   Schmidt, Ann Marie ^b   De Caterina, Raffaele ^a,c  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

Advanced glycation end products; Atherosclerosis; Diabetes; Endothelium; Inflammation

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; CELL ADHESION MOLECULE; HEPARAN SULFATE; HYDRAZINE DERIVATIVE; IMMUNOGLOBULIN; LIPID; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; PLASMA PROTEIN; REACTIVE OXYGEN METABOLITE;

AEROBIC METABOLISM; ATHEROGENESIS; ATHEROSCLEROSIS; BIOCHEMISTRY; BLOOD VESSEL INJURY; BLOOD VESSEL PERMEABILITY; BLOOD VESSEL WALL; CELL ACTIVATION; CELL ADHESION; CELL PROLIFERATION; CHEMICAL STRUCTURE; CLINICAL TRIAL; DIABETES MELLITUS; ENDOCYTOSIS; ENDOTHELIUM CELL; GLYCATION; HUMAN; INFLAMMATORY DISEASE; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LIGAND BINDING; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; VASODILATATION; WILD TYPE;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ARTERIOSCLEROSIS; BLOOD VESSELS; DIABETES COMPLICATIONS; DIABETES MELLITUS; ENDOTHELIUM, VASCULAR; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LIPIDS; MODELS, ANIMAL;

EID: 4043058031     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2004.05.001     Document Type: Review

References (98)

1. Schwartz C.J., Valente A.J., Sprague E.A., et al. Pathogenesis of the atherosclerotic lesion. Implications for diabetes mellitus. Diabetes Care. 15:1992;1156-1167
2. Stamler J., Vaccaro O., Neaton J.D., Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 16:1993;434-444
3. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329:1993;977-986
4. Nathan D. Relationship between metabolic control and long term complications of diabetes. Kahn C.R., Weir G.C. Joslin's diabetes mellitus. 1994;620-631 Lea & Febiger, Philadelphia
5. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N. Engl. J. Med. 342:2000;381-389
6. Kuusisto J., Mykkanen L., Pyorala K., Laakso M. Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. Stroke. 25:1994;1157-1164
7. Colwell J.A. Multifactorial aspects of the treatment of the type II diabetic patient. Metabolism. 46:1997;1-4
8. King G.L., Shiba T., Oliver J., Inoguchi T., Bursell S.E. Cellular and molecular abnormalities in the vascular endothelium of diabetes mellitus. Annu. Rev. Med. 45:1994;179-188
9. Koya D., King G.L. Protein kinase C activation and the development of diabetic complications. Diabetes. 47:1998;859-866
10. Takeuchi M., Yanase Y., Matsuura N., et al. Immunological detection of a novel advanced glycation end-product. Mol. Med. 7:2001;783-791
11. Thornalley P.J., Langborg A., Minhas H.S. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem. J. 344:1999;106-116
12. Miyata T., Horie K., Ueda Y., et al. Advanced glycation and lipid oxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int. 58:2000;425-435
13. Brownlee M., Cerami A., Vlassara H. Advanced glycosylation end-products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 318:1988;1315-1321
14. Vlassara H., Bucala R., Striker L. Pathogenic effect of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab. Invest. 2:1994;138-151
15. Reddy S., Bichler J., Wells-Knecht K., Thorpe S., Baynes J. Carboxymethyllysine is a dominant AGE antigen in tissue proteins. Biochemistry. 34:1995;10872-10878
16. Ikeda K., Higashi T., Sano H., et al. Carboxymethyllysine protein adduct is a major immunological epitope in proteins modified with AGEs of the Maillard reaction. Biochemistry. 35:1996;8075-8083
17. Schleicher E., Wagner E., Nerlich A. Increased accumulation of glycoxidation product carboxymethyllysine in human tissues in diabetes and aging. J. Clin. Invest. 99:1997;457-468
18. Wells-Knecht K.J., Brinkmann E., Wells-Knecht M.C., et al. New biomarkers of Maillard reaction damage to proteins. Nephrol. Dial. Transplant. 11:1996;41-47
19. Odani H., Shinzato T., Usami J., et al. Imidazolium crosslinks derived from reaction of lysine with glyoxal and methylglyoxal are increased in serum proteins of uremic patients: evidence for increased oxidative stress in uremia. FEBS Lett. 427:1998;381-385
20. Degenhardt T.P., Thorpe S.R., Baynes J.W. Chemical modification of proteins by methylglyoxal. Cell. Mol. Biol. (Noisy-le-grand). 44:1998;1139-1145
21. Ferreira A.E., Ponces Freire A.M., Voit E.O. A quantitative model of the generation of N(epsilon)-(carboxymethyl)lysine in the Maillard reaction between collagen and glucose. Biochem. J. 376:2003;109-121
22. Anderson M.M., Hazen S.L., Hsu F.F., Heinecke J.W. Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive alpha-hydroxy and alpha, beta-unsaturated aldehydes by phagocytes at sites of inflammation. J. Clin. Invest. 99:1997;424-432
23. Basta G., Lazzerini G., Massaro M., et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation. 105:2002;816-822
24. Yan S.F., Ramasamy R., Naka Y., Schmidt A.M. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ. Res. 93:2003;1159-1169
25. Kilhovd B.K., Berg T.J., Birkeland K.I., Thorsby P., Hanssen K.F. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care. 22:1999;1543-1548
26. Nakamura Y., Horii Y., Nishino T., et al. Immunohistochemical localisation of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am. J. Pathol. 143:1993;1649-1656
27. Vlassara H., Li Y.M., Imani F., et al. Identification of galectin-3 as a high affinity binding protein for advanced glycation end products (AGEs): a new member of the AGE-receptor complex. Mol. Med. 1:1996;634-646
28. Sims T.J., Rasmussen L.M., Oxlund H., Bailey A.J. The role of glycation cross-links in diabetic vascular stiffening. Diabetologia. 39:1996;946-951
29. Sell D., Monnier V.M. Structure elucidation of senescence cross-link from human extracellular matrix: implication of pentoses in the aging process. J. Biol. Chem. 264:1989;21597-21602
30. Hori O., Brett J., Nagashima M., et al. RAGE is a cellular binding site for amphoterin: mediation of neurite outgrowth and co-expression of RAGE and amphoterin in the developing nervous system. J. Biol. Chem. 270:1995;25752-25761
31. Ritthaler U., Roth H., Bierhaus A., et al. Expression of RAGE in peripheral occlusive vascular disease. Am. J. Pathol. 146:1995;688-694
32. Miyata T., Hori O., Zhang J., et al. RAGE mediates the interaction of AGE-beta-2-microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway: implications for the pathogenesis of dialysis-related amyloidosis. J. Clin. Invest. 98:1996;1088-1094
33. Yan S.D., Chen X., Fu J., et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature. 382:1996;685-691
34. Brownlee M., Vlassara H., Kooney T., Ulrich P., Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science. 232:1986;1629-1632
35. Vlassara H. Advanced glycation end-products and atherosclerosis. Ann. Med. 28:1996;419-426
36. Meng J., Sakata N., Takebayashi S., et al. Glycoxidation in aortic collagen from STZ-induced diabetic rats and its relevance to vascular damage. Atherosclerosis. 136:1998;355-365
37. Tsilbary E.C., Charonis A.S., Reger L.A., Wohlhueter R.M., Furcht L.T. The effect of nonenzymatic glycosylation on the binding of the main noncollagenous NC1 domain to type IV collagen. J. Biol. Chem. 263:1990;4302-4308
38. Charonis A.S., Reger L.A., Dege J.E., et al. Laminin alterations after in vitro nonenzymatic glycosylation. Diabetes. 39:1988;807-814
39. Bucala R., Mitchell R., Arnold K., et al. Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor. J. Biol. Chem. 270:1995;828-832
40. Bucala R., Makita Z., Vega G., et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc. Natl. Acad. Sci. U. S. A. 91:1994;9441-9445
41. Glomb M.A., Monnier V. Mechanism of protein modifications by glyoxal and glyceraldehyde, reactive intermediates of the Maillard reaction. J. Biol. Chem. 270:1995;10017-10026
42. Fu M.X., Requena J.R., Jenkins A.J., et al. The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J. Biol. Chem. 271:1996;9982-9986
43. Klein R.L., Laimins M., Lopes-Virella M.F. Isolation, characterization, and metabolism of the glycated and nonglycated subfractions of low-density lipoproteins isolated from type I diabetic patients and nondiabetic subjects. Diabetes. 44:1995;1093-1098
44. Vlassara H., Brownlee M., Cerami A. Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors. J. Exp. Med. 164:1986;1301-1309
45. Schmidt A.M., Yan S.D., Wautier J.L., Stern D.M. Activation of receptor for advanced glycation end products - a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res. 84:1999;489-497
46. Schmidt A.M., Hasu M., Popov D., et al. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE-proteins. Proc. Natl. Acad. Sci. U. S. A. 91:1994;8807-8811
47. ε-(carboxymethyl) Lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem. 274:1999;31740-31749
48. Mackic J.B., Stins M., McComb J.G., et al. Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1-40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J. Clin. Invest. 102:1998;734-743
49. Schmidt A.M., Vianna M., Gerlach M., et al. Isolation and characterization of binding proteins for advanced glycosylation endproducts from lung tissue which are present on the endothelial cell surface. J. Biol. Chem. 267:1992;14987-14997
50. Neeper M., Schmidt A.M., Brett J., et al. Cloning and expression of a cell surface receptor for advanced glycosylation endproducts of proteins. J. Biol. Chem. 267:1992;14998-15004
51. Brett J., Schmidt A.M., Yan S.D., et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol. 143:1993;1699-1712
52. Tanji N., Markowitz G.S., Fu C., et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J. Am. Soc. Nephrol. 11:2000;1656-1666
53. Schmidt A.M., Yan S.D., Yan S.F., Stern D.M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest. 108:2001;949-955
54. Taguchi A., Blood D.C., del Toro G., et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature. 405:2000;354-360
55. Hofmann M.A., Drury S., Fu C., et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 97:1999;889-901
56. Kislinger T., Tanji N., Wendt T., et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 21:2001;905-910
57. Wendt T., Bucciarelli L., Qu W., et al. Receptor for Advanced Glycation Endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr. Atheroscler. Rep. 4:2002;228-237
58. Yan S.D., Schmidt A.M., Anderson G.M., et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem. 269:1994;9889-9897
59. Wautier M.P., Chappey O., Corda S., et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab. 280:2001;E685-E694
60. Siebenlist U., Franzoso G., Brown K. Structure, regulation and function of NF-kappa B. Annu. Rev. Cell Biol. 10:1994;405-455
61. Schmidt A.M., Hori O., Chen J.X., et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1(VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J. Clin. Invest. 96:1995;1395-1403
62. Lander H., Tauras J., Ogiste J., et al. Activation of the receptor for advanced glycation end products triggers a p21ras-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem. 272:1997;17810-17814
63. Bierhaus A., Chevion S., Chevion M., et al. Advanced glycation end product-induced activation of NF-κB is suppressed by α-lipoic acid in cultured endothelial cells. Diabetes. 46:1997;1481-1490
64. 1. FEBS Lett. 410:1997;481-484
65. Huttunen H.J., Fages C., Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J. Biol. Chem. 274:1999;19919-19924
66. Guh J.Y., Huang J.S., Chen H.C., et al. Advanced glycation end product-induced proliferation in NRK-49F cells is dependent on the JAK2/STAT5 pathway and cyclin D1. Am. J. Kidney Dis. 38:2001;1096-1104
67. Vlassara H., Brownlee M., Manogue K.R., Dinarello C.A., Pasagian A. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science. 240:1988;1546-1548
68. Kirstein M., Brett J., Radoff S., et al. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc. Natl. Acad. Sci. U. S. A. 87:1990;9010-9014
69. Kirstein M., Aston C., Hintz R., Vlassara H. Receptor-specific induction of insulin-like growth factor I (IGF-1) in human monocytes by advanced glycosylation end product-modified proteins. J. Clin. Invest. 90:1992;439-446
70. Schmidt A.M., Yan S.D., Brett J., et al. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J. Clin. Invest. 91:1993;2155-2168
71. Miyata T., Inagi R., Iida Y., et al. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. J. Clin. Invest. 93:1994;521-528
72. Cipollone F., Iezzi A., Fazia M., et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation. 108:2003;1070-1077
73. Sakata N., Meng J., Takebayashi S. Effects of advanced glycation end products on the proliferation and fibronectin production of smooth muscle cells. J. Atheroscler. Thromb. 7:2000;169-176
74. Sakaguchi T., Yan S.F., Yan S.D., et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J. Clin. Invest. 111:2003;959-972
75. Esposito C., Gerlach H., Brett J., Stern D., Vlassara H. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J. Exp. Med. 170:1989;1387-1407
76. Wautier J.L., Zoukourian C., Chappey O., et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J. Clin. Invest. 97:1996;238-243
77. Bierhaus A., Illmer T., Kasper M., et al. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation. 96:1997;2262-2271
78. Cybulsky M.I., Gimbrone M.A. Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 251:1991;788-791
79. Li H., Cybulsky M.I., Gimbrone M.A. Jr., Libby P. Inducible expression of vascular cell adhesion molecule-1 by vascular smooth muscle cells in vitro and within rabbit atheroma. Am. J. Pathol. 143:1993;1551-1559
80. Bucala R., Tracey J., Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J. Clin. Invest. 87:1991;432-438
81. De Caterina R., Libby P., Peng H.B., et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J. Clin. Invest. 96:1995;60-68
82. Quehenberger P., Bierhaus A., Fasching P., et al. Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. Diabetes. 49:2000;1561-1570
83. Vlassara H., Fuh H., Makita Z., et al. Exogenous advanced glycosylation endproducts induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc. Natl. Acad. Sci. U. S. A. 89:1992;12043-12047
84. Vlassara H., Striker L.J., Teichberg S., et al. Advanced glycation endproducts induce glomerular sclerosis and albuminuria in normal rats. Proc. Natl. Acad. Sci. U. S. A. 91:1994;11704-11708
85. Vlassara H., Fuh H., Donnelly T., Cybulsky M. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol. Med. 1:1995;447-456
86. Park L., Raman K.G., Lee K.J., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 4:1998;1025-1031
87. Bucciarelli L.G., Wendt T., Qu W., et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation. 106:2002;2827-2835
88. Zhou Z., Wang K., Penn M.S., et al. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation. 107:2003;2238-2243
89. Chavakis T., Bierhaus A., Al-Fakhri N., et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J. Exp. Med. 198:2003;1507-1515
90. Rahbar S., Figarola J.L. Novel inhibitors of advanced glycation endproducts. Arch. Biochem. Biophys. 419:2003;63-79
91. Edelstein D., Brownlee M. Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes. 41:1992;26-28
92. Huijberts M.S.P., Wolffenbuttel B.R.H., Struijker Boudier H.A.J. Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J. Clin. Invest. 92:1993;1407-1411
93. Freedman B.I.W.J., Cartwright K., Bain R.P., Dippe S., Hershon K., Mooradian A.D., Spinowitz B.S. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control. Clin. Trials. 20:1999;493-510
94. Vasan S., Zhang X., Zhang X., et al. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature. 382:1996;275-278
95. Cooper M.E., Thallas V., Forbes J., et al. The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation. Diabetologia. 43:2000;660-664
96. Vasan S., Foiles P.G., Founds H.W. Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links. Expert Opin. Investig. Drugs. 10:2001;1977-1987
97. Bierhaus A., Schiekofer S., Schwaninger M., et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes. 50:2001;2792-2808
98. Hofmann M.A., Drury S., Hudson B.I., et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun. 3:2002;123-135